DLX 0110

Drug Profile

DLX 0110

Alternative Names: DLX0110

Latest Information Update: 07 Aug 2007

Price : $50

At a glance

  • Originator DELEX Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 04 May 2005 DELEX Therapeutics has been acquired by YM BioSciences
  • 27 Aug 2003 Preclinical trials in Pain in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top